Annually, more than 3,000 tons of a wide range of herbal extracts and natural active substances are extracted at Xi'an Konochemical Co.,Ltd manufacturing plant near Xi'an, China. These extracts are in compliance with worldwide GMP norms, international Pharmacopoeias, and international regulations.

The botanical raw materials are subject to strict selection and inspection, and extracts are manufactured according to methods developed by Konochemical. They include inspections to guarantee a high quality standard from both analytico-chemical and therapeutic points of view, and take into consideration the state of art in different fields: research and development, analyses, processes and machinery, therapeutic applications on a scientific basis.

Basic information

Product name: Baicalin

Assay: 98% min

CAS No: 21967-41-9

Plant source; Scutellaria baicalensis Georgi root, S.scordifolia Fisch.(S.galericulata L., Oroxylum indicum(L.), Plantago major L.

Molecular formula: C21H18O11

Molecular weight: 446.35

Specifications: ≥98% HPLC

Characteristics: yellow crystalline, melting point 223~225°C,flavonone glycosides

Main Functions

Baicalin is one of the flavonoids found in the radix of Scutellaria baicalensis that has antioxidant activity.

It scavenges hydroxyl radical, DPPH radical and alkyl radical, and protects cells from oxidative damage. Baicalin also exhibits a variety of biological activities. Its antiinflammatory effect was observed by its inhibition against carrageenan-induced rat paw edema. It has anti-HIV activity. The replication of HIV-1 was inhibited in a dose-dependent manner. One of the mechanisms of inhibition is likely the induction of apoptosis.

Baicalin was found also to inhibit colon aberrant crypts formation induced by azoxymethane and suppressed the growth and metastasis of malignant melanoma in ret-transgenic mice.

Baicalin was extensively researched for utility in a number of therapeutic areas owing to its anti-inflammatory, anti-oxidant, anti-bacterial, and anti-cancer properties. A number of preclinical studies, in vitro work, and mechanistic studies were performed to understand the absorption, distribution, metabolism, and excretion profiles of baicalin. The absorption of baicalin involved several complexities: the restriction to two distant sites; the conversion of baicalin to baicalein; the possible role of transporter(s); and enhanced absorption due to breakdown of conjugates by beta-glucuronidase. Limited distribution data suggest that baicalin reached several sites such as the brain, eye lens, thymus, etc. Hepatobiliary recycling also served as a distribution phase for sustained delivery of baicalin. Metabolism data suggest the rapid conversion of baicalin to baicalein, which was extensively subjected to Phase 2 metabolism, conjugates baicalein glucuronide/sulfate have been identified. Limited excretion data suggest involvement of renal and faecal routes--glucuronide and sulfate conjugates were excreted in urine and faeces (via biliary excretion). The published data on baicalin suggest imminent challenges for developing baicalin and/or during co-administration with other agents. These challenges are absorption related (transporter or changes in the microenvironment), metabolism related (CYP2B6 induction and/or CYP2E1 inhibition), and excretion/efflux related (competitive biliary pathway and/or OATP1B1 transport).